THE ANTIMALARIA EFFECT OF IRON CHELATORS - STUDIES IN ANIMAL-MODELS AND IN HUMANS WITH MILD FALCIPARUM-MALARIA

被引:48
作者
HERSHKO, C
GORDEUK, VR
THUMA, PE
THEANACHO, EN
SPIRA, DT
HIDER, RC
PETO, TEA
BRITTENHAM, GM
机构
[1] CASE WESTERN RESERVE UNIV, METROHEALTH MED CTR, DEPT MED, CLEVELAND, OH 44106 USA
[2] PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PEDIAT, HERSHEY, PA 17033 USA
[3] HEBREW UNIV JERUSALEM, HADASSAH MED SCH, KUVIN CTR STUDY TROP & INFECT DIS, IL-91010 JERUSALEM, ISRAEL
[4] NUFFIELD DEPT MED, OXFORD, ENGLAND
[5] UNIV LONDON KINGS COLL, CHELSEA DEPT PHARM, LONDON WC2R 2LS, ENGLAND
关键词
D O I
10.1016/0162-0134(92)84072-U
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study we explore the antimalarial effects of 3-hydroxypyridin-4-ones (CP compounds), a family of bidentate orally effective iron chelators in experimental animal systems in vivo and in vitro, and examine whether the iron chelator deferoxamine (DF) is active against human infection with P. falciparum. There was direct relation between lipid solubility of the CP compounds, which would facilitate membrane transit, and their in vivo antimalarial action, suggesting direct intracellular iron chelation as the most likely explanation for the antimalarial effect of iron chelators. Results of the double-blind, placebo controlled trial of DF in humans with asymptomatic parasitemia provided unequivocal evidence that this iron-chelating agent has antimalarial activity. Depriving the parasite of a metabolically important source of iron may represent a novel approach to antimalarial drug development. DF is a relatively ineffective intraerythrocytic chelator, and our data indicate that other orally effective iron chelators may have superior antimalarial activity in vivo. A systematic screening of available iron chelating drugs may result in the identification of potentially useful antimalarial compounds.
引用
收藏
页码:267 / 277
页数:11
相关论文
共 30 条